Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP

Global pharma major Lupin Limited (Lupin) has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg, to market a generic equivalent of Antivert® Tablets, 12.5 mg, 25 mg, and 50 mg, of Casper Pharma LLC. The product will be manufactured at Lupin's facility in Goa, India.

Meclizine Hydrochloride Tablets (RLD Antivert®) had estimated annual sales of USD 29 million in the U.S. (IQVIA MAT June 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 682.60 as compared to the previous close of Rs. 689.90. The total number of shares traded during the day was 25660 in over 1211 trades.

The stock hit an intraday high of Rs. 695.00 and intraday low of 681.10. The net turnover during the day was Rs. 17583730.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 ANDAApproval USFDA MeclizineHydrochlorideTablets